The Corporation focussed on the biology of healing last week made two announcements, that between them underpin how efficiently the firm is advancing is Plasma Derived Therapeutics, whilst at the same time attracting valuable third party revenues from its proprietary technology platform, which is the backbone of the biologic drug discovery programme.
11 Apr 2017
Strong progress from existing and future business activities
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong progress from existing and future business activities
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
11 Apr 2017 -
Author:
Derren Nathan -
Pages:
6
The Corporation focussed on the biology of healing last week made two announcements, that between them underpin how efficiently the firm is advancing is Plasma Derived Therapeutics, whilst at the same time attracting valuable third party revenues from its proprietary technology platform, which is the backbone of the biologic drug discovery programme.